Our research focuses on the development of innovative therapeutic drugs aimed at treating Rett Syndrome, a rare genetic neurological disorder. By targeting specific genetic pathways, we aim to improve neurological function and quality of life for patients.
March 2023 – Our lead asset, KIT-13, was granted Orphan Drug Designation (ODD) for the treatment of Rett Syndrome. Currently in the preclinical stage, KIT-13 is undergoing extensive evaluation to ensure its safety and efficacy. The first clinical trial is planned for the near future, marking a significant step toward addressing the unmet needs of patients with Rett Syndrome.
For detail Click here